Literature DB >> 31907180

Forging New Antibiotic Combinations under Iron-Limiting Conditions.

Derek C K Chan1, Irene Guo1, Lori L Burrows2.   

Abstract

Pseudomonas aeruginosa is a multidrug-resistant nosocomial pathogen. We showed previously that thiostrepton (TS), a Gram-positive thiopeptide antibiotic, is imported via pyoverdine receptors and synergizes with iron chelator deferasirox (DSX) to inhibit the growth of P. aeruginosa and Acinetobacter baumannii clinical isolates. A small number of P. aeruginosa and A. baumannii isolates were resistant to the combination, prompting us to search for other compounds that could synergize with TS against those strains. From literature surveys, we selected 14 compounds reported to have iron-chelating activity, plus one iron analogue, and tested them for synergy with TS. Doxycycline (DOXY), ciclopirox olamine (CO), tropolone (TRO), clioquinol (CLI), and gallium nitrate (GN) synergized with TS. Individual compounds were bacteriostatic, but the combinations were bactericidal. Our spectrophotometric data and chrome azurol S agar assay confirmed that the chelators potentiate TS activity through iron sequestration rather than through their innate antimicrobial activities. A triple combination of TS plus DSX plus DOXY had the most potent activity against P. aeruginosa and A. baumannii isolates. One P. aeruginosa clinical isolate was resistant to the triple combination but susceptible to a triple combination containing higher concentrations of CLI, CO, or DOXY. All A. baumannii isolates were susceptible to the triple combinations. Our data reveal a diverse set of compounds with dual activity as antibacterial agents and TS adjuvants, allowing combinations to be tailored for resistant clinical isolates.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumannii; Pseudomonas aeruginosa; chelator; iron; thiostrepton

Year:  2020        PMID: 31907180      PMCID: PMC7038247          DOI: 10.1128/AAC.01909-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  66 in total

Review 1.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

2.  Thiostrepton Hijacks Pyoverdine Receptors To Inhibit Growth of Pseudomonas aeruginosa.

Authors:  Michael R M Ranieri; Derek C K Chan; Luke N Yaeger; Madeleine Rudolph; Sawyer Karabelas-Pittman; Hamdi Abdo; Jessica Chee; Hanjeong Harvey; Uyen Nguyen; Lori L Burrows
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos.

Authors:  D W Kamp; V A Israbian; A V Yeldandi; R J Panos; P Graceffa; S A Weitzman
Journal:  Toxicol Pathol       Date:  1995 Nov-Dec       Impact factor: 1.902

Review 4.  Iron uptake regulation in Pseudomonas aeruginosa.

Authors:  Pierre Cornelis; Sandra Matthijs; Liesbeth Van Oeffelen
Journal:  Biometals       Date:  2009-01-08       Impact factor: 2.949

5.  Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis.

Authors:  Alessandro Fiori; Patrick Van Dijck
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

6.  Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

Authors:  Sophie Moreau-Marquis; George A O'Toole; Bruce A Stanton
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-23       Impact factor: 6.914

7.  The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.

Authors:  Brian B Hasinoff; Daywin Patel; Xing Wu
Journal:  Free Radic Biol Med       Date:  2003-12-01       Impact factor: 7.376

8.  Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia.

Authors:  F Heath Damron; Amanda G Oglesby-Sherrouse; Angela Wilks; Mariette Barbier
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

9.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

10.  A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus.

Authors:  Mia Gi; Kang-Mu Lee; Sang Cheol Kim; Joo-Heon Yoon; Sang Sun Yoon; Jae Young Choi
Journal:  Sci Rep       Date:  2015-10-08       Impact factor: 4.379

View more
  5 in total

Review 1.  Thiopeptides: antibiotics with unique chemical structures and diverse biological activities.

Authors:  Derek C K Chan; Lori L Burrows
Journal:  J Antibiot (Tokyo)       Date:  2020-12-21       Impact factor: 2.649

2.  Biofilm-specific uptake of a 4-pyridone-based iron chelator by Pseudomonas aeruginosa.

Authors:  Sharareh Houshmandyar; Ian M Eggleston; Albert Bolhuis
Journal:  Biometals       Date:  2021-01-11       Impact factor: 2.949

3.  Effect of iron chelation on anti-pseudomonal activity of doxycycline.

Authors:  M E Faure; A Cilibrizzi; V Abbate; K D Bruce; R C Hider
Journal:  Int J Antimicrob Agents       Date:  2021-09-20       Impact factor: 5.283

Review 4.  Antimicrobial activity of clioquinol and nitroxoline: a scoping review.

Authors:  Rachel Wykowski; Alexandre Meneghello Fuentefria; Saulo Fernandes de Andrade
Journal:  Arch Microbiol       Date:  2022-07-30       Impact factor: 2.667

Review 5.  Metallotherapeutics development in the age of iron-clad bacteria.

Authors:  Garrick Centola; Fengtian Xue; Angela Wilks
Journal:  Metallomics       Date:  2020-12-23       Impact factor: 4.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.